A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma-Reference-Cited by-同舟云学术

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Published:2019-01 Issue:1 Volume:19 Page:29-34
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Ailawadhi Sikander^ORCID,Kelly Kevin R.,Vescio Robert A.,Jagannath Sundar,Wolf Jeffrey,Gharibo Mecide,Sher Taimur,Bojanini Leyla,Kirby Maurice,Chanan-Khan Asher

Funder

Pharmacyclics

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. Cancer Statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients;Blimark;Haematologica,2015

3. Review of 1027 patients with newly diagnosed multiple myeloma;Kyle;Mayo Clin Proc,2003

4. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group;Laubach;Leukemia,2016

5. Multiple myeloma;Smith;BMJ,2013

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond BCMA: newer immune targets in myeloma;Blood Advances;2024-08-16

2. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement;Drug Resistance Updates;2024-07

3. Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions;Pharmaceuticals;2024-06-25

4. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma;Expert Review of Anticancer Therapy;2024-05-26

5. Exploring cellular immunotherapy platforms in multiple myeloma;Heliyon;2024-03